Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression

Figure 2

Effect of TAS106 on radiosensitivity of A549, HEp-2 and V79 cell lines. (A-C) Dose-response curves for cells exposed to X-irradiation with or without indicated concentrations of TAS106. After the pretreatment with TAS106, cells were irradiated and assessed for its radiosensitizing effect by measuring clonogenic cell survival. (A) Clonogenic cell survival for A549 cells. Closed circle; X-irradiation only, open circle; X-irradiation + 0.5 μM TAS106, closed square; X-irradiation + 0.75 μM TAS106, open square; X-irradiation + 1 μM TAS106. (B) Clonogenic cell survival for HEp-2 cells. Closed circle; X-irradiation only, open square; X-irradiation + 0.1 μM TAS106. (C) Clonogenic cell survival for V79 cells. Closed circle; X-irradiation only, open square; X-irradiation + 1 μM TAS106. Data are expressed as mean ± SE of three experiments.

Back to article page